8-K - ORGS - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934

Date of Report (Date of earliest event reported): October30, 2023

ORGENESIS

INC.

(Exact name of registrant as specified in its charter)

Nevada	001-38416	98-0583166
(State or Other Jurisdiction	(Commission File	(IRS Employer
of Incorporation)	Number)	Identification No.)

20271 Goldenrod Lane, Germantown, MD 20876

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (480) 659-6404

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ORGS	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 30, 2023, Orgenesis Inc. (the “Company”) announced that it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions. As a result of such termination, no securities will be sold pursuant to the proposed underwritten public offering. A copy of the press release issued in connection therewith is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

This Current Report on Form 8-K is not an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Item 9.01. Financial Statements and Exhibits.

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

Exhibit No.	Description
99.1	Press Release dated October 30, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ORGENESIS INC.
Date: October 31, 2023	By:	/s/ Elliot Maltz
		Elliot Maltz
		Chief Financial Officer, Treasurer and
		Secretary

Exhibit 99.1

Orgenesis Announces Withdrawal of Proposed PublicOffering

Germantown, Maryland – October 30, 2023 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Orgenesis

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnership to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. Additional information about the Company is available at: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements.All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefsand expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projectionsand reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-lookingstatements are predictions based on our current expectations about future events. These forward-looking statements are not guaranteesof future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performanceor achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors,including, but not limited to, the expected deconsolidation of Octomera from our consolidated financial statements, our reliance on, andour ability to grow, our point-of-care cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability,our ability to manage our research and development programs that are based on novel technologies, our ability to control key elementsrelating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinicaltrials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses andbenefits of our product candidates, our ability to manage potential disruptions as a result of the COVID-19 pandemic, the sufficiencyof working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy,our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioningas expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfillour obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitorsdeveloping better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertaintiesdiscussed under the heading “RISK FACTORS” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-lookingstatement for any reason.

Investor relations contact for Orgenesis:

Crescendo Communications, LLC

Tel: 212-671-1021

Orgs@crescendo-ir.com

Communications contact for Orgenesis

IB Communications

Neil Hunter / Michelle Boxall